Century Therapeutics, Inc. (IPSC) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Century Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $0 | $109.2 million | $1.6 million |
| Net Income (Loss) | $(32.5) million | $44.0 million | $(59.3) million |
| Operating Expenses | $34.7 million | $69.7 million | $67.7 million |
| Cash & Cash Equivalents | As of June 30, 2025: $56.9 million | ||
| Short-term Investments | |||
| Total Liquidity (Cash + Investments) | As of June 30, 2025: $158.5 million | ||
| Accumulated Deficit | As of June 30, 2025: $(738.3) million |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $109.2 million in collaboration revenue in Q1 2025 due to the termination of its agreement with Bristol-Myers Squibb (BMS). No collaboration revenue was recognized in Q2 2025. This resulted in a net income of $44.0 million for the six months ended June 30, 2025, compared to a net loss of $59.3 million in the same period in 2024.
- Operating Expenses: Total operating expenses increased slightly year-over-year for the six-month period ($69.7M vs $67.7M). Research and Development (R&D) expenses rose by $2.8 million, driven by a $4.8 million increase in research and laboratory costs, partially offset by reductions in personnel and facility costs.
- Cash Flow: Net cash used in operating activities was $62.2 million for the six months ended June 30, 2025, compared to $57.6 million in the prior year. Investing activities provided $60.5 million in cash, primarily from the sale of fixed maturity securities.
Outlook, Risks, and Unusual Items
- Strategic Reprioritization: In March 2025, the company discontinued the evaluation of its lead candidate, CNTY-101, for lymphoma. The focus has shifted to autoimmune diseases and pre-clinical programs (CNTY-308, CNTY-341).
- Workforce Reduction: In July 2025 (subsequent event), the company completed a reduction in force of approximately 51% of its workforce. The company expects to incur approximately $4.3 million in severance and related costs, primarily in Q3 2025.
- Liquidity: Management believes current cash and investment resources ($158.5 million) are sufficient to fund operations into the fourth quarter of 2027. However, the company anticipates needing additional financing in the future.
- Risks: Key risks include the early clinical nature of the business, dependence on the success of product candidates, reliance on third-party manufacturers (FCDI), and the need to raise additional capital. The company has a full valuation allowance against its deferred tax assets.
- Subsequent Legislation: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. The company is evaluating the impact on deferred tax assets and effective tax rates but has not recognized any tax effects in this filing.
Investor Verification Checklist
- Verify the sustainability of the $109.2 million revenue spike, which was a one-time recognition from the BMS termination and will not recur.
- Confirm the timeline and cost impact of the 51% workforce reduction and the expected $4.3 million severance expense in Q3 2025.
- Assess the progress of the re-prioritized pipeline (CNTY-308, CNTY-341) and the status of the CNTY-101 autoimmune disease trial.
- Monitor the company's cash burn rate post-restructuring to validate the runway estimate into late 2027.
- Review the terms of the ongoing collaboration with FUJIFILM Cellular Dynamics (FCDI) regarding manufacturing and licensing.